Breaking News

Sirona Biochem Receives $500,000 Milestone from Wanbang

CFDA approves Phase I clinical trial for Sirona's SGLT-2 inhibitor

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sirona Biochem has received a $500,000 milestone payment from partner Wanbang Biopharmaceuticals for approval by the China Food and Drug Administration (CFDA) of the Phase I clinical trial for Sirona’s SGLT-2 inhibitor. Sirona’s SGLT-2 inhibitor, TFC-039, will continue to be developed for the treatment of Type 2 diabetes. Since the two companies signed a licensing agreement in 2014, Sirona Biochem has secured $1.5 million in development milestones from Wanbang. Shortly after the a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters